Importantly, during the last few years, immunotherapy has made considerable progress in HCC treatment and the combination of ICIs and the VEGF inhibitor (atezolizumab plus bevacizumab) is currently the first-line treatment for patients with advanced HCC [11,12]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.